As risk factor, IL-2Rα expression might be outcompeted by more intense treatment regimens with brentuximab-vedotin (BV)-containing regimens or SCT in our adult ALCL, ALK− cohort. Here, IL2RA is linked to anaplastic large cell lymphoma.